Company Profile

Botanisol Analytics Inc
Profile last edited on: 8/19/21      CAGE: 86CD4      UEI: VAQKP4LEARF2

Business Identifier: Rapid digital virus screening: biological threat detection
Year Founded
2017
First Award
2019
Latest Award
2020
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

275 North Gateway Drive Suite 150
Phoenix, AZ 85034
   (623) 256-1282
   info@bsol.io
   www.botanisolholdings.com
Location: Single
Congr. District: 07
County: Maricopa

Public Profile

In the context of Corvid crisis, redefining themselves as a cutting-edge biological threat detection technology company Botanisol Analytics - under a sponsored research agreement - is performing, a pre-clinical study with Beth Israel Deaconess Medical Center (BIDMC), an academic medical center affiliated with Harvard Medical School (HMS). The project was/is designed to validate the firm's rapid digital pathogen screening system for SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic. Botanisol Analytics is developing a screening tool, not a diagnostic. Subject to CFR820.30 molecular testing and verification standards. The Botanisol test has not been reviewed, cleared, approved, or authorized for emergency use by the U.S. Food and Drug Administration (FDA) but (so far) is not currently available in the United States. Addressing the challenge of improving measurements and analytics with engineering and science, having facilities and firm associated personnel in Ph Botanisol Analytics, a cutting-edge biological threat detection technology company, is performing, under a sponsored research agreement, a pre-clinical study with Beth Israel Deaconess Medical Center (BIDMC), an academic medical center affiliated with Harvard Medical School (HMS), that was designed to validate its rapid digital pathogen screening system for SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic. oenix, AZ, Boston, MA and Westmount Canada, Botanisol had previously been organized around development of non-steroidal anti-inflammatory drugs from bio-active constituents of plants that are natural and organic and pose lesser threat to human bodies. Using a previously unavailable wavelength of light to analyze the molecular makeup of samples in seconds, the firm offers molecular detection instrumentation - a spectrometer capable of detecting and quantifying chemical compositions while gathering data on a molecular level. Providing valuable and accurate information enables clients to access their instrument to determine molecular makeup of crops and processed goods. Having worldwide exclusive rights to patented technology from the University of Arizona, Botanisol equipment can determine the molecular composition of substances in near real time. With the initial target market being Agriculture, the systen can detect and quantify dangerous or advantageous materials quickly and efficiently.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Key People / Management

  David Talenfeld -- CEO

  James Foley -- Chief Technology Officer

  David Gang -- Co-Founder & Chief Scientific Officer

  Kristian Marquez -- Chief Financial Officer

  Scott Waterhouse -- Chief Executive Officer and Founder

Company News

There are no news available.